Abstracts tagged "treatment"

Abstract Number: 1510 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Seung-jae Kim¹, Zhenlong Chen¹, Abdul Essani², Michael Volin³, Suncica Volkov¹, William Swedler⁴, Shiva Arami², Nadera J. Sweiss⁵ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Microbiology & Immunology, Midwestern University, Downers Grove, IL, ⁴Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, ⁵internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: TLR5 expression is highly elevated in RA and CIA lining and sublining macrophages and endothelial cells compared to non-arthritic controls. Additionally, expression of TLR5…
Abstract Number: 2815 • 2014 ACR/ARHP Annual Meeting
Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
T. Martijn Kuijper¹, J.J. Luime¹, P.H.P. de Jong², A. H. Gerards³, D. van Zeben⁴, I. Tchetverikov⁵, P.B.J. de Sonnaville⁶, M. van Krugten⁷, B. Grillet⁸, J.M.W. Hazes⁹ and A.E.a.M. Weel^10,11, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁷Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁸Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹⁰Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ¹¹Rheumatology, MD, PhD, Rotterdam, Netherlands
Background/Purpose: To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to…
Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Iain B. McInnes¹, Gerd Burmester², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, David Close⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, Sara Sandbach¹², Patricia C. Ryan¹³, Dominic Sinibaldi¹⁴, Wendy White¹³, Nadine A. Defranoux¹⁵ and Michael Weinblatt¹⁶, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, ⁷Med Clinic I, University of Cologne, koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹³Translational Sciences, MedImmune, Gaithersburg, MD, ¹⁴R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, ¹⁵Crescendo Bioscience Inc., South San Francisco, CA, ¹⁶Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel^®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)
Sang-Cheol Bae¹, Jinseok Kim², Jung-Yoon Choe³, Won Park⁴, So-Ra Lee⁵, Yongho Ahn⁶ and Yunjeong Seo⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Internal Medicine, Jeju National University, Jeju, Korea, South Korea, ³Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁵Clinical Development/Regulatory Affairs, Hanwha Chemical, Seoul, South Korea, ⁶R&D Center, Hanwha Chemical, Daejeon, South Korea, ⁷Clinical Development, Hanwha Chemical, Seoul, South Korea
Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…
Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Julie Hambleton¹, Lei Zhou¹, Seema Rogers¹, Sjoerd van Marle², Thijs van Iersel², James Zanghi¹, Emma Masteller¹, Kevin Baker¹ and Brian Wong¹, ¹Five Prime Therapeutics, South San Francisco, CA, ²PRA Health Sciences, Groningen, Netherlands
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…
Abstract Number: 2826 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate
Mark C. Genovese¹, Maria Greenwald², Christine Codding³, Mario H. Cardiel⁴, Anna Zubrzycka-Sienkiewicz⁵, Alan J. Kivitz⁶, Steve Wisseh⁷, Kathyjo Shay⁸ and Jay P. Garg⁸, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Desert Medical Advances, PALM DESERT, CA, ³Health Research of Oklahoma, Oklahoma City, OK, ⁴Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁵ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Biocis, Chicago, IL, ⁸Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: 1356 • 2014 ACR/ARHP Annual Meeting
Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care
Alan K. Matsumoto¹, Herbert S. B. Baraf², Bruce Feinberg³, Phil Miller⁴ and Daniel Winn⁴, ¹Rheumatology, Arthritis & Rheumatism Associates, PC, Wheaton, MD, ²Arthritis & Rheumatism Associates, PC, Wheaton, MD, ³Cardinal Health, Dublin, OH, ⁴CareFirst BlueCross, Baltimore, MD
Background/Purpose Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…
Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Stacey Chang¹, Laura Sawyer¹ and Fred Dejonckheere², ¹Symmetron Limited, London, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
Abstract Number: 948 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Alan J. Kivitz¹, Anna Zubrzycka-Sienkiewicz², Sergio R. Gutierrez-Ureña³, Jeffrey Poiley⁴, Rita Kristy⁵, Kathyjo Shay⁵ and Jay P. Garg⁵, ¹Altoona Center for Clinical Research, Duncansville, PA, ²ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ³Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, ⁴Arthritis Associates, Orlando, FL, ⁵Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis
Charles Inderjeeth¹, Andrew Redfern¹, Michael Huang², Yun Hardiman², Theresa Grant², Lawrence C. Fritz², David Fuller³, David Haughey⁴ and Mark C. Totoritis², ¹Linear Clinical Research Ltd, Perth, Australia, ²Santarus, Inc., San Diego, CA, ³INC Research, Inc., New South Wales, Australia, ⁴ICON Development Solutions, Whitesboro, NY
Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].